FDA rejects Sesen Bio's bladder cancer pitch, sending shares spiraling back to penny stock territory

Sesen Bio received some bad news Friday afternoon that it said was “unexpected,” briefly slashing shares by more than 80% and below $1 for the …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA re­jects Sesen Bio's blad­der can­cer pitch, send­ing shares spi­ral­ing back to pen­ny stock ter­ri­to­ry